Open Access

ESR1, HK3 and BRSK1 gene variants are associated with both age at natural menopause and premature ovarian failure

  • Yingying Qin1,
  • Mei Sun1,
  • Li You1,
  • Deying Wei2,
  • Jielin Sun3,
  • Xiaoyan Liang4,
  • Bo Zhang5,
  • Hong Jiang6,
  • Jianfeng Xu7 and
  • Zi-Jiang Chen1Email author
Orphanet Journal of Rare Diseases20127:5

https://doi.org/10.1186/1750-1172-7-5

Received: 13 October 2011

Accepted: 17 January 2012

Published: 17 January 2012

Abstract

Background

Premature ovarian failure (POF) is a complex and heterogeneous disorder that is influenced by multiple genetic components. Numerous candidate gene studies designed to identify POF susceptibility loci have been published, but most positive findings have not been confirmed in follow up studies. We sought to determine if sequence variants previously associated with age at natural menopause (AANM) or early menopause (EM) contribute as well to genetic susceptibility to POF.

Methods

Our study was performed on 371 unrelated idiopathic women with POF and 800 women controls, all Chinese Han. Thirty six SNPs from previous genome-wide association studies (GWAS) responsible for AANM or EM and 3 additional SNPs in ESR1, and 2 additional SNPs in PTHB1 were tested using the Sequenom MassARRAY iPLEX platform for genotyping.

Results

Three SNPs - rs2278493 in HK3, rs2234693 in ESR1 and rs12611091 in BRSK1 - showed nominally significant association with POF. Thus, a plausible relationship could exist between ESR1, BRSK1, HK3 and POF.

Conclusions

This largest association study undertaken to determine correlation between POF and AANM/EM revealed three significant SNPs (rs2278493, rs2234693, and rs12611091). All are associated with not only AAWM and EM but also POF. Insights into shared genetic susceptibility between POF and AANM/EM will provide novel entry points for unraveling genetic mechanism involved in ovarian reserve and oocyte aging processes.

Keywords

Premature ovarian failure (POF) Primary ovarian insufficiency (POI) Age at natural menopause (AANM) HK3 ESR1 BRSK1 Premature menopause Hypergonadotropic hypogonadism

Background

Natural menopause is one of the most important physiological events, the cessation of ovarian function and the end of the reproductive lifespan. Twin and family studies indicate high heritability for age at natural menopause (AANM) (49-87%) [1]. The AANM in Chinese women is approximately 49 years [2]. Early onset of menopause increases risk for many postmenopausal health complications. Menopause occurring between 40 and 44 years has an incidence of 5% and is termed early menopause (EM) [3]. Premature ovarian failure (POF), also termed as primary ovarian insufficiency (POI), is defined as ovarian failure before the age 40 years [4, 5].

POF is characterized by secondary amenorrhea, hypoestrogenism and elevated gonadotropin serum levels (FSH > 40 IU/L). Approximately 1% of the population has POF before age 40 years; only 0.1% or less are affected prior to age 30. Although most cases of POF occur sporadically, approximately 10 - 15% of cases have an affected first-degree relative [6]. Based on either known roles in folliculogenesis or phenotypes of murine knockout models, many candidate genes have been interrogated to determine their role in POF. However, except for FSHR in Finnish women none explains more than 1-2% of POF in any given ethnic group [7]. Genes whose perturbations cause POF have nonetheless been identified in single patients or families, small patient groups or selected ethnic groups. This may reflect genetic heterogeneity, ethnic-specific genetic variation or failure to interrogate sufficient numbers of the candidate genes that could potentially account for POF.

Via genome-wide association studies (GWASs), it is possible to identify common genetic variants contributing to susceptibility to genetically complex or polygenic diseases. Despite the attractiveness of GWAS for POF, genome searches in a sufficiently large number of patients are practically absent [8]. Kang H.J. et al. showed association of two SNPs (rs3884597 and rs6944723) in the PTH-responsive B1 gene (PTHB1) in a small discovery set of 24 women and 24 controls, followed by confirmation in 101 cases and 87 controls [9]. The other GWAS showed association with ADAMTS19 in the discovery set of 99 Dutch women and 181 controls, but not in the replication set (60 POF cases and 90 controls) [10]. That 8% of the relatives of women with POF in Chinese suffer from either early menopause or POF (Table 1) suggests an interrelated genetic mechanism between POF and early menopause. Indeed, Tibiletti et al. proposed that POF and EM patients share similar genetic features and postulated that these conditions may be a variable expression of the same genetic disease [11]. Additionally, FMR1 is a single gene cause of POF, and it is clinically indicated to test for premutation in this gene. Genes like EIF2B5 and FMR1 that are known to be involved in POF have been reported to be associated also with AANM [1214]. Few studies have explored the shared genetic associations among POF, AANM and EM. On the basis of four independent GWAS, 36 SNPs have been associated with AANM. These are located on chromosomes 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 15, 18, 19 and 20, respectively, with robust statistical evidence. Of these, 2 SNPs were related to EM [1, 15, 16]. Besides these 36 SNPs, we also assessed correlation between POF and three additional SNPs in the estrogen receptor 1 (ESR1) gene, given the key role of ER-α in folliculogenesis. ESR1 has also been considered a promising candidate gene for POF, with rs2234693, rs9340799 and rs1569788 of ESR1 reported to be associated with idiopathic POF [1719]. ESR1 also has been one of the most popular candidates related with AANM in previous association studies [20, 21].
Table 1

Clinical features of cases and controls, which are not significantly different (p > 0.05).

Characteristic

 

Cases

 

   Number

371

   FSH concentration (IU/L)a

73.88 ± 30.23

   Familial clusteringb

32

Mother affected

27

Menopause < 40 yrs

13

40 yrs < Menopause < 45 yrs

14

Siblings affected

5

Menopause < 40 yrs

5

   Age at diagnosis (yrs)a

29.79 ± 5.31

Amenorrhea Secondary

228

Age at menarche (yrs)a

14.82 ± 2.11

Age at onset of menstrual dysfunction (yrs)a

23.85 ± 6.78

Age at amenorrhea (yrs)a

24.87 ± 5.88

Controls

 

   Number

800

   Age(yrs)a at sample

38.77 ± 11.58

   Age at menarche(yrs)a

14.75 ± 1.45

a ± SD

b Defined as two or more first-or second-degree female family members with either POF or early menopause (less than 45 years old), including the index POF patient.

Overall, we sought to determine the contribution to POF of the 36 SNPs from AANM GWAS, the 3 SNPs in the ESR1 gene and the 2 SNPs in the PTHB1 gene. Our association study involved 371 women with POF and 800 controls, all Chinese Han.

Methods

Participants and phenotypes

Our study was performed on 371 unrelated idiopathic women with POF and 800 women controls, all Chinese Han, collectively gathered from a number of high volume regional referral centers in China. Samples were collected from 18 provinces during 2002-2010. The age of secondary amenorrhea in our sample was young (mean age 23.85 ± 6.78 years) (Table 1). 8% (32/400) of cases had a positive family history, i.e., at least two first-or second-degree female family members with POF or early menopause including the index POF patient. Most of the affected relatives (27/32; thirteen < 40 yrs and fourteen < 45 yrs) were mothers of the index patient; the remaining five were sisters. Inclusion criteria for POF consisted of cessation of menstrual cycles before 40 years of age, with at least two serum follicle stimulating hormone (FSH) concentrations exceeding 40 IU/L. Serum FSH level was determined by the electrochemiluminescent immunoassay in the analyzer cobas e 601 (Roche, Switzerland). The analytical sensitivity of basal FSH was < 0.10 mIU/ml. All samples were run in the same assay. Early menopause is defined as menopause that occurs between ages 40 and 44. Women with known chromosomal abnormalities, previous ovarian surgery, chemotherapy, or radiotherapy were excluded. Controls attended the clinic because of tubal factor infertility. They were known to be menstruating regularly and confirmed by hormone assays (< 40 mIU/L) and ultrasound imaging to be free of POF-related and early menopause- related phenotypes. Informed consent was obtained from all subjects. The study was approved by the Institutional Review Board of Reproductive Medicine of Shandong University.

Genotyping and statistical analysis

SNPs were chosen for genotyping on the basis of published findings in association studies. A total of 41 SNPs are located in LHCGR, PPARG, SRD5A1, HK3, RAP80, SYCP2L, TNF, ESR1, IGF2R, PTHB1, NBN, TGFBR1, FSHB, PGR, ANKK1, IGF1, CYP19A1, POLG, SMAD7, BRSK1, TMEM150B, MCM8 or intergenic region (Table 2). We used the Sequenom MassARRAY iPLEX platform for genotyping. The Sequenom protocol involves a multiplex PCR reaction prior to a single-base primer extension reaction. The individual SNPs are identified by using matrix-assisted laser desorption/ionization time- of- fight mass spectrometry. SNPs were excluded if the minor allele frequency was < 1%. Ultimately, 36 SNPs were genotyped in the case control cohort. Allelic association analysis was conducted using SHEsis [22]. The genotype distributions for all SNPs were tested for Hardy-Weinberg equilibrium (HWE) using the Fisher's exact test. All SNPs were in Hardy- Weinberg equilibrium. The allelic odds ratio (OR) and 95% confidence interval (CI) were estimated assuming a multiplicative model. P-values were two-tailed. An alpha of 0.05 was used to claim statistical significance.
Table 2

Loci selected for association analysis in POF and controls.

All samples (371 cases and 800 controls)

Gene information

Phenotype related

CHR

BP

SNP

F_MISS

HWE_P

A1

F_A

F_U

A2

P

OR

  

3

12423994

rs4135280

0.008333

0.2789

C

0.2861

0.2738

T

0.5321

1.063

PPARG

AANM

5

6692179

rs494958

0.009167

0.3597

T

0.2263

0.2237

A

0.8881

1.015

SRD5A1

AANM

5

176247040

rs2278493

0.008333

0.08305

A

0.3451

0.3881

G

0.0432

0.8309

HK3

AANM

5

176255904

rs691141

0.0175

0.682

T

0.4747

0.4608

C

0.5302

1.057

HK3

AANM

5

176290671

rs7718874

0.01083

0.4156

T

0.4696

0.4765

C

0.7525

0.9726

RAP80

AANM

5

176311180

rs365132

0.0175

0.4133

C

0.4669

0.4744

A

0.7343

0.9704

RAP80

AANM

5

176367046

rs402511

0.01833

0.293

C

0.4707

0.4769

T

0.7792

0.9755

RAP80

AANM

5

176436169

rs244715

0.01083

0.3229

A

0.4842

0.4703

G

0.5254

1.058

intergenic

EM

6

11005474

rs2153157

0.0275

0.5569

G

0.3484

0.335

A

0.5233

1.061

SYCP2L

AANM

6

31648292

rs909253

0.01333

0.0382

C

0.4134

0.3829

T

0.1564

1.136

TNF

AANM

6

152205028

rs2234693

0.01

0.7176

C

0.3655

0.4217

T

0.009057

0.79

ESR1

POF/AANM

6

152205074

rs9340799

0.006667

0.7148

G

0.189

0.2016

A

0.4703

0.9228

ESR1

POF/AANM

6

152370309

rs1569788

0.008333

0.7268

T

0.453

0.474

C

0.338

0.9191

ESR1

POF/AANM

6

160419555

rs2297362

0.008333

0.9062

C

0.4301

0.4383

T

0.7047

0.9669

IGF2R

AANM

6

160423646

rs9457827

0.01417

0.9059

T

0.4312

0.4379

C

0.7602

0.9732

IGF2R

AANM

7

33351787

rs3884597

0.009167

0.222

T

0.467

0.4784

G

0.6047

0.9554

PTHB1

POF

7

33390485

rs6944723

0.01083

1

A

0.4459

0.4183

T

0.2051

1.119

PTHB1

POF

8

91019056

rs2697679

0.009167

0.5546

G

0.4195

0.437

T

0.4217

0.931

NBN

AANM

8

91082415

rs7011299

0.015

0.5509

G

0.4237

0.4202

C

0.8727

1.014

NBN

AANM

9

100955986

rs1590

0.0075

0.1803

G

0.4581

0.466

T

0.7184

0.9687

TGFBR1

AANM

11

30196754

rs11031010

0.0125

0.4482

A

0.04319

0.04047

C

0.7559

1.07

FSHB

AANM

11

112786283

rs6279

0.0075

0.05507

C

0.4619

0.4747

G

0.5609

0.9501

ANKK1

AANM

13

111017433

rs1361542

0.005833

0.396

A

0.03665

0.03391

G

0.7332

1.084

intergenic

AANM

13

111017854

rs1756091

0.006667

0.3965

A

0.03655

0.03461

C

0.8101

1.058

intergenic

AANM

13

111019298

rs7333181

0.0075

0.3965

A

0.03655

0.03465

G

0.8143

1.057

intergenic

AANM

13

111019632

rs1163623

0.003333

0.3965

C

0.03627

0.03457

T

0.8326

1.051

intergenic

AANM

15

49335997

rs11856927

0.005833

0.6833

C

0.4532

0.4641

A

0.6187

0.9572

CYP19A1

AANM

15

87670333

rs2351002

0.01083

0.5205

G

0.3521

0.3398

C

0.5542

1.056

POLG

AANM

18

44721958

rs4939833

0.0075

0.1067

G

0.03403

0.04203

A

0.3495

0.803

SMAD7

AANM

19

60492141

rs12611091

0.005833

0.8633

T

0.2422

0.2001

C

0.01892

1.278

BRSK1

AANM

19

60506693

rs1551562

0.01917

0.161

G

0.06016

0.06974

A

0.3858

0.8539

BRSK1

AANM

19

60511657

rs1172822

0.008333

0.384

T

0.0953

0.09046

C

0.7026

1.059

BRSK1

AANM

19

60516144

rs7246479

0.0075

0.4537

C

0.1929

0.1895

A

0.8435

1.022

BRSK1

AANM

19

60523000

rs2384687

0.006667

0.4769

C

0.08877

0.09023

T

0.9072

0.9822

TMEM150B

AANM

19

60525476

rs11668344

0.005833

0.4762

C

0.08724

0.08962

T

0.8488

0.9709

TMEM150B

AANM

19

60525566

rs897798

0.0075

0.6029

C

0.08924

0.09383

T

0.7183

0.9463

TMEM150B

AANM

11

30203352

rs621686

0.01417

1

G

0.002653

0.00062

A

0.1956

4.285

FSHB

AANM

11

30218544

rs7951733

0.003333

1

G

0

0.000617

A

0.4899

0

FSHB

AANM

11

100477546

rs619487

0.003333

1

C

0.003886

0.006173

A

0.4769

0.6281

PGR

AANM

12

101388555

rs1019731

0.0075

1

T

0.002611

0.003094

G

0.8388

0.8435

IGF1

AANM

20

5896227

rs16991615

0.01167

1

A

0.001316

0.001241

G

0.9617

1.061

MCM8

EM

CRH: Chromosome; SNP: Single-nucleotide polymorphism; HWE_P: Hardy-Weinberg principle; F_A, F_U indicate the allele frequency in cases and controls, respectively

Results

We analyzed 41 SNPs for association with POF in our collection of 400 cases and 800 controls. The analysis was nominally significant for three SNPs: rs2278493 in HK3, rs2234693 in ESR1 and rs12611091 in BRSK1, respectively. Results are summarized in Table 2. These findings demonstrate that certain SNPs associated with AANM also may contribute to POF, but need not necessarily play a major role in POF. No significant association with POF was observed for the remaining 38 SNPs.

Discussion

We conducted the largest association study reported to date in a POF cohort in order to test the contribution to POF of 36 SNPs, specifically known to be associated with AANM and EM. We also investigated the associations of 3 ESR1 SNPs and 2 PTHB1 SNPs in POF. We found contribution to POF for SNPs in ESR1, BRSK1 and HK3, 2 of these genes not previously considered as candidates for POF.

Estrogen regulates cyclic gonadotropin release at the hypothalamus- hypophysis- ovarian (HPO) axis by the estrogen receptor α (ER-α), which is encoded by ESR1 and enhances follicular development by the ER-β encoded by ESR2. Female ER-α knockout mice show anovulation and complete infertility. Rs2234693 lies in an intron of the ESR1gene and has been reported to be related to POF and the onset of natural menopause in Korean and Dutch [1719], consistent with our results. Because this SNP does not change any amino acid in the ERS1 protein, it is presumed to be in linkage disequilibrium with a regulatory sequence(s) that could affect gene expression or function and consequently result in an alteration in estrogenic biological activity.

Rs12611091 is located in the intron region of BRSK1 (BR serine/threonine kinase 1), a gene that codes for an AMP-activated protein kinase (AMPK)-related kinase [23]. BRSK1 is highly expressed in human brain and moderately expressed in mammalian ovaries [24]. Mutation or overexpression of the BRSK1 gene deleteriously affects vesicle transport and release at the axon terminals [25]. BRSK1 might affect the secretion of gonadotropin- releasing hormone (GnRH) from the hypothalamus through this mechanism. Additionally, maternal embryonic leucine zipper kinase (MELK), which is highly expressed in spermatogonia and oocytes, is one of the downstream targets of BRSK1 [26, 27]. Plausible involvement in ovarian aging is therefore suggested for BRSK1.

Hexokinase 3 (white cell) (HK3), one of the four hexokinase family members, is involved in carbohydrate metabolism through phosphorylating glucose to produce glucose-6-phosphate [28]. HK3 is present in uterus, placenta, lung and adipose according to GeneAtlas [24]. Literature analysis for HK3 did not indicate an immediate functional explanation for the observed association. To elucidate the precise molecular mechanism, extensive sequence analysis and functional studies of the HK3gene variants are needed.

Idiopathic POF and EM differ in age of menopause onset and have long been considered to represent variable expression of the same genetic disease [11]. It is highly plausible that certain genes might contribute to both. That is, similar underlying genetic predisposition exists, possibly with different environmental factors or modifiers triggering disease progression and, hence, specific age of onset. Another possibility is that certain genes in pathways ordinarily predisposing only to EM interact or converge to cause even earlier age of onset, i.e, below age 40 and thus lead to clinical POF.

Conclusions

In summary, our data demonstrate that genetic susceptibility for both AANM/EM and POF is shared by the ESR1, HK3 and BRSK1 genes. This became evident by our showing that three SNPs previously related to AANM were associated with POF. At these newly identified loci fine mapping or sequencing might lead to identification of causal variants, and thus expand our knowledge of the underlying mechanism of POF. Insights into shared genetic susceptibility between POF and AANM/EM will further provide novel entry points for unraveling etiology involved in ovarian reserve and aging process. Identifying genetic causation may further be of diagnostic value to other family members, especially female offspring. If a younger relative has the same genetic variant, timeline for achieving pregnancy might be advanced and early child-bearing encouraged.

List of abbreviations

AANM: 

age at natural menopause

EM: 

early menopause

POF: 

premature ovarian failure

POI: 

primary ovarian insufficiency

GWAS: 

genome-wide association study

PTHB1: 

PTH-responsive B1 gene

ESR1: 

estrogen receptor 1

FSH: 

follicle stimulating hormone

SNP: 

single nucleotide polymorphism

HPO: 

hypothalamus- hypophysis- ovarian

ER-α: 

estrogen receptor α

AMPK: 

AMP-activated protein kinase

MELK: 

maternal embryonic leucine zipper kinase

BRSK1: 

BR serine/threonine kinase 1

GnRH: 

gonadotropin- releasing hormone

HK3: 

Hexokinase 3 (white cell).

Declarations

Acknowledgements

We thank all the participants involved in this study. Supported by grants from the National Basic Research Program of China (973 Program-2012CB944700, 2010CB945002, 2007CB947403, 2007CB948103), A Foundation for the Author of National Excellent Doctoral Dissertation of PR China (201078), the National Natural Science Foundation of China (30973170, 81000236, 81000238), Science research foundation item of no-earnings health vocation from Ministry of Public Health (201002013).

Authors’ Affiliations

(1)
Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, The Key laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Key Laboratory of Reproductive Medicine
(2)
Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University
(3)
Center for Cancer Genomics, Wake Forest University School of Medicine
(4)
Center for Reproductive Medicine, the Sixth Affiliated Hospital of Sun Yat-Sen University
(5)
Center for Reproductive Medicine, Maternal and Child Health Hospital in Guangxi
(6)
Center for Reproductive Medicine
(7)
Fudan-VARI Center for Genetic Epidemiology, Fudan University

References

  1. Stolk L, Zhai G, van Meurs JB, Verbiest MM, Visser JA, Estrada K, Rivadeneira F, Williams FM, Cherkas L, Deloukas P, Soranzo N, de Keyzer JJ, Pop VJ, Lips P, Lebrun CE, van der Schouw YT, Grobbee DE, Witteman J, Hofman A, Pols HA, Laven JS, Spector TD, Uitterlinden AG: Loci at chromosomes 13, 19 and 20 influence age at natural menopause. Nat Genet. 2009, 41: 645-647. 10.1038/ng.387.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Nie GN, Wang XY, Yang HY, Aihua Ou: The investigation and analysis of the factors related with the menopausal age of urban women in China. China maternal and child healthcare (Chinsese). 2011, 8: 1191-1193.Google Scholar
  3. Chang SH, Kim CS, Lee KS, Kim H, Yim SV, Lim YJ, Park SK: Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007, 58: 19-30. 10.1016/j.maturitas.2007.04.001.View ArticlePubMedGoogle Scholar
  4. De Vos M, Devroey P, Fauser BC: Primary ovarian insufficiency. Lancet. 2010, 376: 911-921. 10.1016/S0140-6736(10)60355-8.View ArticlePubMedGoogle Scholar
  5. Nelson LM: Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009, 360: 606-614. 10.1056/NEJMcp0808697.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Simpson JL: Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci. 2008, 1135: 146-154. 10.1196/annals.1429.019.View ArticlePubMedGoogle Scholar
  7. Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila EM, Lehvaslaiho H, Engel AR, Nieschlag E, Huhtaniemi I, de la Chapelle A: Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995, 82: 959-968. 10.1016/0092-8674(95)90275-9.View ArticlePubMedGoogle Scholar
  8. Christin-Maitre S, Tachdjian G: Genome-wide association study and premature ovarian failure. Ann Endocrinol (Paris). 2010, 71: 218-221. 10.1016/j.ando.2010.02.014.View ArticleGoogle Scholar
  9. Kang H, Lee SK, Kim MH, Song J, Bae SJ, Kim NK, Lee SH, Kwack K: Parathyroid hormone-responsive B1 gene is associated with premature ovarian failure. Hum Reprod. 2008, 23: 1457-1465. 10.1093/humrep/den086.View ArticlePubMedGoogle Scholar
  10. Knauff EA, Franke L, van Es MA, van den Berg LH, van der Schouw YT, Laven JS, Lambalk CB, Hoek A, Goverde AJ, Christin-Maitre S, Hsueh AJ, Wijmenga C, Fauser BC: Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod. 2009, 24: 2372-2378. 10.1093/humrep/dep197.View ArticlePubMedGoogle Scholar
  11. Tibiletti MG, Testa G, Vegetti W, Alagna F, Taborelli M, Dalpra L, Bolis PF, Crosignani PG: The idiopathic forms of premature menopause and early menopause show the same genetic pattern. Hum Reprod. 1999, 14: 2731-2734. 10.1093/humrep/14.11.2731.View ArticlePubMedGoogle Scholar
  12. Fogli A, Gauthier-Barichard F, Schiffmann R, Vanderhoof VH, Bakalov VK, Nelson LM, Boespflug-Tanguy O: Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failure. BMC Womens Health. 2004, 4: 8-10.1186/1472-6874-4-8.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Conway GS: Premature ovarian failure and FMR1 gene mutations: an update. Ann Endocrinol (Paris). 2010, 71: 215-217. 10.1016/j.ando.2010.02.009.View ArticleGoogle Scholar
  14. He C, Kraft P, Chasman DI, Buring JE, Chen C, Hankinson SE, Pare G, Chanock S, Ridker PM, Hunter DJ: A large-scale candidate gene association study of age at menarche and age at natural menopause. Hum Genet. 2010, 128: 515-527. 10.1007/s00439-010-0878-4.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Murray A, Bennett CE, Perry JR, Weedon MN, Jacobs PA, Morris DH, Orr N, Schoemaker MJ, Jones M, Ashworth A, Swerdlow AJ: Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study. Hum Mol Genet. 2011, 20: 186-192. 10.1093/hmg/ddq417.PubMed CentralView ArticlePubMedGoogle Scholar
  16. He C, Kraft P, Chen C, Buring JE, Pare G, Hankinson SE, Chanock SJ, Ridker PM, Hunter DJ, Chasman DI: Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet. 2009, 41: 724-728. 10.1038/ng.385.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Kim S, Pyun JA, Cha DH, Ko JJ, Kwack K: Epistasis between FSHR and CYP19A1 polymorphisms is associated with premature ovarian failure. Fertil Steril. 2011Google Scholar
  18. Yoon SH, Choi YM, Hong MA, Lee GH, Kim JJ, Im HJ, Min EG, Kang BM, Yoon BK, Moon SY: Estrogen receptor {alpha} gene polymorphisms in patients with idiopathic premature ovarian failure. Hum Reprod. 2010, 25: 283-287. 10.1093/humrep/dep375.View ArticlePubMedGoogle Scholar
  19. Bretherick KL, Hanna CW, Currie LM, Fluker MR, Hammond GL, Robinson WP: Estrogen receptor alpha gene polymorphisms are associated with idiopathic premature ovarian failure. Fertil Steril. 2008, 89: 318-324. 10.1016/j.fertnstert.2007.03.008.View ArticlePubMedGoogle Scholar
  20. Yang JJ, Cho LY, Lim YJ, Ko KP, Lee KS, Kim H, Yim SV, Chang SH, Park SK: Estrogen receptor-1 genetic polymorphisms for the risk of premature ovarian failure and early menopause. J Womens Health (Larchmt). 2010, 19: 297-304. 10.1089/jwh.2008.1317.View ArticleGoogle Scholar
  21. Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman A, Helmerhorst TJ, van Leeuwen JP, Pols HA: Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab. 1999, 84: 3146-3150. 10.1210/jc.84.9.3146.PubMedGoogle Scholar
  22. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15: 97-98. 10.1038/sj.cr.7290272.View ArticlePubMedGoogle Scholar
  23. Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, Raines AN, Sanes JR, Polleux F: LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell. 2007, 129: 549-563. 10.1016/j.cell.2007.03.025.View ArticlePubMedGoogle Scholar
  24. GeneAtlas. [http://genatlas.medecine.univ-paris5.fr/]
  25. Lu R, Niida H, Nakanishi M: Human SAD1 kinase is involved in UV-induced DNA damage checkPOFnt function. J Biol Chem. 2004, 279: 31164-31170. 10.1074/jbc.M404728200.View ArticlePubMedGoogle Scholar
  26. Kishi M, Pan YA, Crump JG, Sanes JR: Mammalian SAD kinases are required for neuronal polarization. Science. 2005, 307: 929-932. 10.1126/science.1107403.View ArticlePubMedGoogle Scholar
  27. Thelie A, Papillier P, Pennetier S, Perreau C, Traverso JM, Uzbekova S, Mermillod P, Joly C, Humblot P, Dalbies-Tran R: Differential regulation of abundance and deadenylation of maternal transcripts during bovine oocyte maturation in vitro and in vivo. BMC Dev Biol. 2007, 7: 125-10.1186/1471-213X-7-125.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Nakamura N, Shibata H, O'Brien DA, Mori C, Eddy EM: Spermatogenic cell-specific type 1 hexokinase is the predominant hexokinase in sperm. Mol Reprod Dev. 2008, 75: 632-640. 10.1002/mrd.20791.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Qin et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement